<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 9-Oct | 6:00-7:00 AM | Novel Cancer Therapeutics and Cancer Prevention | Multilevel Interventions in Cancer Prevention and Control: A Community-Based Translational Research Framework to Address Prostate Cancer Disparities | Brian Rivers, PhD, MPH  
Director of the Cancer Health Equity Institute  
Morehouse School of Medicine (MSM) |  
| 9-Oct | 7:30-8:30 AM | Tumor Drug Resistance and Tumor Evolution | Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia | Ernesto Diaz-Flores, PhD  
Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF |  
| 9-Oct | 9:00-10:00 AM | Novel Cancer Therapeutics and Cancer Prevention | Start at the End: A Strategy for Developing and Delivering Advanced Diagnostic Tests to improve Prostate Cancer Patient Outcomes | Stephen Pennington  
Professor of Proteomics, Founder, CEO and CSO  
Atturos Ltd.  
C/O UCD Conway Institute  
University College Dublin |  
| 9-Oct | 10:30-11:30 AM | Tumor Drug Resistance and Tumor Evolution | A practical guide for multiplexed ion beam imaging to reveal tumor immunobiology | Selena Ferrian  
Sr.Staff Scientist/LSRP3, Stanford University |  
| 9-Oct | 10:30-11:30 AM | Novel Cancer Therapeutics and Cancer Prevention | Newly Diagnosed Ovarian Cancer: Surgical Options | Mitchel S. Hoffman, MD  
Full-time faculty member, Department of Gynecologic Oncology,  
Moffitt Cancer Center, and Professor, USF Morsani College of Medicine |  
| 9-Oct | 12:00-1:00 PM | Molecular Guidance Versus Standard of Care | Next Steps in Personalized Medicine- Using Genomics and Imaging For Treatment Selection in Early Stage Prostate Cancer | Anson Tharayanil  
Medical Science Liaison (Urology), Genomic Health, Inc. |  
| 9-Oct | 12:00-1:00 PM | Novel Cancer Therapeutics and Cancer Prevention | What is New in Surgical Management of Invasive Bladder Cancer in 2020 | Khurshid Guru, MD  
Surgeon, Dept of Urology, Chair, Dept of Urology, Director,  
Applied Technology Laboratory for Advanced Surgery, Robert P.  
Huben Endowed Professor of Oncology, Roswell Park Cancer Institute |  
| 9-Oct | 1:30-2:30 PM | Tumor Drug Resistance and Tumor Evolution | Tumor processing for the isolation and visualization of Tumor Infiltrating Leukocytes | Josh Mahlios, PhD  
Senior Marketing Product Manager, Miltenyi Biotec |  
| 10-Oct | 6:00-7:00 AM | Novel Cancer Therapeutics and Cancer Prevention | Highly-efficient and -specific genome editing with Cas9 nickase ribonucleoproteins in Primary T-cells | Jacob Lamberth  
R&D Scientist, Genome and Epigenome Editing: MilliporeSigma |  
| 10-Oct | 7:30-8:30 AM | Novel Cancer Therapeutics and Cancer Prevention | Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families | Ernest Hawk, MD, MPH  
Vice President & Division Head for Cancer Prevention &  
Population Sciences, University of Texas MD Anderson Cancer Center |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Title</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-Oct</td>
<td>9:00-10:00 AM</td>
<td>Tumor Drug Resistance and Tumor Evolution</td>
<td>Dynamic evolution of unstable genomes: insights from in vitro experiments and cancer genome analysis</td>
<td>Cheng-Zhong Zhang, PhD Assistant Professor, Biomedical Informatics, Harvard Medical School, and Assistant Professor, Biostatistics &amp; Computational Biology, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>10-Oct</td>
<td>9:00-10:00 AM</td>
<td>Novel Cancer Therapeutics and Cancer Prevention</td>
<td>Next Generation Targets for Immuno-Oncology</td>
<td>Anthony Persen, PhD Sr. Director, Protein Business Unit, R&amp;D Systems</td>
</tr>
<tr>
<td>10-Oct</td>
<td>10:30-11:30 AM</td>
<td>Molecular Guidance Versus Standard of Care</td>
<td>Transcriptional Profiling of the Pediatric Tumor Microenvironment</td>
<td>Troy McEachron, PhD Assistant Professor of Research, Translational Genomics, University of Southern California, Keck School of Medicine</td>
</tr>
<tr>
<td>10-Oct</td>
<td>10:30-11:30 AM</td>
<td>Tumor Drug Resistance and Tumor Evolution</td>
<td>Whole genome imaging for sensitive and accurate analysis of structural variations in cancer</td>
<td>Sven Bocklandt, PhD Director, Scientific Affairs, Bionano Genomics</td>
</tr>
<tr>
<td>10-Oct</td>
<td>12:00-1:00 PM</td>
<td>Tumor Drug Resistance and Tumor Evolution</td>
<td>Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care</td>
<td>Ravindra Kolhe, MD, PhD Associate Professor, Pathology; Associate Director, Residency Program; Medical Director, Cytogenetics Laboratory AUMC.</td>
</tr>
<tr>
<td>10-Oct</td>
<td>1:30-2:30 PM</td>
<td>Molecular Guidance versus Standard of Care</td>
<td>Precision oncology: Biomarkers for treatment selection in metastatic castration resistant prostate cancer</td>
<td>Tian Zhang, MD, MHS Assistant Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute</td>
</tr>
</tbody>
</table>